Aclaris Therapeutics (ACRS) Reports Q2 Loss of $0.56/Share

Aclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.56), versus ($0.62) reported last year.

2017 Financial Outlook

Aclaris reiterates the following financial guidance:

• Net cash burn for 2017 estimated to be in the range of $65 million to $70 million excluding $10 million used for Confluence acquisition as well as potential financing activities and other potential acquisitions of complementary businesses or technologies.
• Total operating expenses for 2017 estimated to be in the range of $84 million to $92 million, or $70 million to $75 million when excluding estimated stock-based compensation expense of $14 million to $17 million (without giving effect to additional stock-based compensation expense for employees who joined Aclaris as part of the Confluence acquisition).
• Research and development expenses for 2017 estimated to be in the range of $51 million to $58 million, or $46 million to $52 million when excluding estimated stock-based compensation expense of $5 million to $6 million (without giving effect to anticipated expenses associated with the integration of Confluence’s business).

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Esquire Financial sets final exchange ratio for Signature merger